BRWM
CMPX icon

B. Riley Wealth Management’s Compass Therapeutics CMPX Stock Holding History

B. Riley Wealth Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$40K Hold
14,918
– – ﹤0.01% 672
2022
Q1 		$20K Buy
+14,918
New +$30.8K ﹤0.01% 622

Other funds holding CMPX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

B. Riley Wealth Management's CMPX Position: Q2 2022 in Review

B. Riley Wealth Management held its Compass Therapeutics (CMPX) position steady in Q2 2022 at 14,918 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #672.

B. Riley Wealth Management first reported a position in CMPX in Q1 2022 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold CMPX as of Q2 2022.

  • B. Riley Wealth Management held 14,918 shares of Compass Therapeutics worth $40K as of Q2 2022.
  • B. Riley Wealth Management left its Compass Therapeutics share count unchanged in Q2 2022.
  • Compass Therapeutics made up ﹤0.01% of B. Riley Wealth Management's portfolio in Q2 2022, its #672 holding.
  • B. Riley Wealth Management first reported a position in Compass Therapeutics in Q1 2022 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2022.

Based on B. Riley Wealth Management's 13F filing for Q2 2022, filed 9 Sep 2022.